UNSPSC 51112708: Picoplatin

This classification denotes a platinum compound with the molecular structure C6H7N.2CL.PT.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B5TAN0L720 chemically known as platinum, amminedichloro(2-methylpyridine)-, (sp-4-3)-, but more commonly known as picoplatin, which bears US NIH Compound Identifier 177358. European Medicines Agency schedules Picoplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29605.

The term PICOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49). Picoplatin bears US NLM identifiers UMLS ID C0671135 and NCI Concept Code C48416. Most nations, for tariff and trade purposes, schedule picoplatin under HS 28439000 and SITC 52432. SMILES: CC1CCCCN1.N.[CL-].[CL-].[PT+2].

UNSPSC 51112708 Picoplatin is a Commodity code that captures state and local procurement of pharmaceutical active ingredients and specialty chemical compounds used in medicinal formulations and clinical therapeutics. Based on recent state and local activity, the code reflects demand for direct-to-manufacturer access to specialty pharmaceuticals and prescription fulfillment mechanisms that bypass traditional pharmacy benefit manager and group purchasing organization intermediaries. State health agencies and self-insured employee health plans use this code to solicit vendors capable of establishing direct supply relationships and negotiating value-based or outcomes-based pricing models for pharmaceutical products. The issuing-body mix includes state health and human services departments as primary buyers, alongside self-insured employers and government employee health plans seeking cost management and supply-chain efficiency in prescription fulfillment.

Texas Health and Human Services Commission posted Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicits detailed vendor responses regarding experience with direct contracting for self-insured employers and health plans within the past two years, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The state plans to use vendor responses from this preliminary information-gathering phase to develop detailed procurement specifications, pricing models, and implementation timelines for subsequent formal solicitations. The RFI does not specify set-aside designations, budget ranges, or award values at this foundational stage.